JP2019509265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509265A5 JP2019509265A5 JP2018541394A JP2018541394A JP2019509265A5 JP 2019509265 A5 JP2019509265 A5 JP 2019509265A5 JP 2018541394 A JP2018541394 A JP 2018541394A JP 2018541394 A JP2018541394 A JP 2018541394A JP 2019509265 A5 JP2019509265 A5 JP 2019509265A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- motomeko
- cells
- recombinant
- cells according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294251P | 2016-02-11 | 2016-02-11 | |
| US62/294,251 | 2016-02-11 | ||
| US201662294987P | 2016-02-12 | 2016-02-12 | |
| US62/294,987 | 2016-02-12 | ||
| PCT/US2017/017588 WO2017139725A1 (en) | 2016-02-11 | 2017-02-12 | Subcutaneous delivery of adenovirus with dual targeting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509265A JP2019509265A (ja) | 2019-04-04 |
| JP2019509265A5 true JP2019509265A5 (cg-RX-API-DMAC7.html) | 2020-03-19 |
Family
ID=59563571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541394A Pending JP2019509265A (ja) | 2016-02-11 | 2017-02-12 | 二重標的化によるアデノウイルスの皮下送達 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190091316A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3413909A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019509265A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180102707A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109069598A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017218445A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3014056A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261037A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017139725A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3735984A1 (en) * | 2016-05-27 | 2020-11-11 | Etubics Corporation | Neoepitope vaccine compositions and methods of use thereof |
| KR20210010678A (ko) | 2016-06-30 | 2021-01-27 | 난트 홀딩스 아이피, 엘엘씨 | 난트 암 백신 |
| US12653874B2 (en) | 2016-06-30 | 2026-06-16 | Immunitybio, Inc. | Nant cancer vaccine |
| AU2017305396A1 (en) * | 2016-08-02 | 2019-02-21 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
| US11839655B2 (en) | 2017-09-01 | 2023-12-12 | Microvax, Llc | Combination cancer therapy |
| GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
| EP3827262A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| US20220133823A1 (en) * | 2018-09-10 | 2022-05-05 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2404689T3 (es) * | 2001-04-05 | 2013-05-28 | The Johns Hopkins University | Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2 |
| KR101114784B1 (ko) * | 2002-11-12 | 2012-02-27 | 예일 유니버시티 | 아데노바이러스 벡터 백신 |
| FR2993716B1 (fr) * | 2012-07-20 | 2016-09-02 | Thales Sa | Antenne d'emission et de reception multifaisceaux a plusieurs sources par faisceau, systeme d'antennes et systeme de telecommunication par satellite comportant une telle antenne |
| AU2013296919A1 (en) * | 2012-07-30 | 2015-01-22 | Alex Wah Hin Yeung | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator |
| AU2014251207B2 (en) * | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2017
- 2017-02-12 EP EP17750935.3A patent/EP3413909A4/en not_active Withdrawn
- 2017-02-12 AU AU2017218445A patent/AU2017218445A1/en not_active Abandoned
- 2017-02-12 KR KR1020187026204A patent/KR20180102707A/ko not_active Ceased
- 2017-02-12 CA CA3014056A patent/CA3014056A1/en not_active Abandoned
- 2017-02-12 CN CN201780011041.2A patent/CN109069598A/zh active Pending
- 2017-02-12 JP JP2018541394A patent/JP2019509265A/ja active Pending
- 2017-02-12 WO PCT/US2017/017588 patent/WO2017139725A1/en not_active Ceased
- 2017-02-12 US US16/075,874 patent/US20190091316A1/en not_active Abandoned
-
2018
- 2018-08-07 IL IL261037A patent/IL261037A/en unknown
-
2021
- 2021-08-30 US US17/461,319 patent/US20210386844A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells | |
| JP6928380B2 (ja) | B7タンパク質をコードする腫瘍溶解性アデノウイルス | |
| Diehl et al. | In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway | |
| Morgan et al. | Adoptive cell therapy: genetic modification to redirect effector cell specificity | |
| Chen et al. | XCL1/glypican-3 fusion gene immunization generates potent antitumor cellular immunity and enhances anti–PD-1 efficacy | |
| US20220185861A1 (en) | Methods and compositions for treating cancer | |
| US20100240585A1 (en) | In vivo cell surface engineering | |
| AU2017233072B2 (en) | Multimodal vector for dendritic cell infection | |
| Zamarin et al. | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer | |
| CN109952309A (zh) | 用于细胞治疗的组成型活性细胞因子受体 | |
| Strbo et al. | Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| CN111868077A (zh) | Gpi锚定抗原的增强的免疫原性 | |
| JP2019524773A (ja) | 樹状細胞のトランスフェクション及びその方法 | |
| AU2017218445A1 (en) | Subcutaneous delivery of adenovirus with dual targeting | |
| CN108085340A (zh) | 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体 | |
| JP2020532287A (ja) | 癌の治療のためのネオアンチゲンワクチン組成物 | |
| Xu et al. | T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins | |
| Ragonnaud et al. | An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression | |
| Schmittnaegel et al. | A new class of bifunctional major histocompatibility class I antibody fusion molecules to redirect CD8 T cells | |
| Xie et al. | Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application | |
| CN115397439A (zh) | 表达通用免疫受体的工程化细胞活性的定量控制 | |
| Truscott et al. | Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides | |
| Gato-Cañas et al. | Novel immunotherapies for the treatment of melanoma | |
| WO2025049742A1 (en) | Systems and methods for generating multivalent mosaic hla nanoparticles for personalized immunotherapy applications |